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ARTICLE IN PRESSCasein is the main proteinaceous component of milk,
where it accounts for ca. 80% of the total protein
inventory. Until recently, the main physiological role of
casein in the milk system was widely accepted to be a
source of amino acids required by growth of the
neonate. However, the dominant physiological feature
of the casein micelle system has more recently been
proven to be the prevention of pathological calciﬁcation
of the mammary gland (Holt, 1997).
While no speciﬁc physiological property has been
proposed for the whole casein system (or its individual
fractions, for that matter), various peptides hidden
(or inactive) in the amino-acid sequence have been the
subject of increasingly intense studies. Much work
regarding those peptides, which are known to possess
bioactivities, is currently underway regarding their
release via selective enzymatic hydrolysis. Until now,
such release has been demonstrated primarily in vitro,
and to a lower extent in vivo using animal models.
Experimental veriﬁcation of the effectiveness of such
bioactive peptides involving human subjects is, however,
still scarce. Due to the increasing awareness of the effect
of food ingredients upon promotion of health, several
publications have arisen that cover recent advances on
milk peptide research (Clare, Catignani, & Swaisgood,
2003; Florisa, Recio, Berkhout, & Visser, 2003; Janecka,
Fichna, & Janecki, 2004; Kilara & Panyam, 2003; Kitts
& Weiler, 2003; Korhonen & Pihlanto, 2003; Lonnerdal,
2003; Meisel & FitzGerald, 2003; Pellegrini, 2003;
Pihlanto & Korhonen, 2003; Teschemacher, 2003;
Wal, 2002; Walker-Smith, 2003).
This paper intends to provide an overview of the
major classes of bioactive peptides putatively derived
from caseins, which play a role in the nervous,
cardiovascular, digestive and immune systems (Fig. 1),
and a brief critical discussion of the most recent data
made available in the literature regarding that growing
family of molecules.Functional peptides derived from casein, present in
either milk or dairy products, have been shown to have
effects in the cardiovascular system, mainly via antith-
rombotic and antihypertensive features (Tables 1 and 2,
respectively).
The mechanisms involved in the clotting of milk,
deﬁned as the interaction of k-casein with coagulating
enzyme, and in the clotting of blood, deﬁned as the
interaction of ﬁbrinogen with thrombin, have beenproved to be similar in nature (Fiat, Migliore, & Joll"es,
1993; Joll"es, 1975; Joll"es & Henschen, 1982). In
addition, structural homologies between the undecapep-
tide (viz. residues 106–116) from cow’s k-casein, on the
one hand, and the C-terminal dodecapeptide (viz.
residues 400–411) of human ﬁbrinogen g-chain, on the
other, have been duly reported (Joll"es, Loucheux-
Lefebvre, & Henschen, 1978). Indeed, three amino-acid
residues (viz. Ile108, Lys112 and Asp115) of the afore-
mentioned undecapeptide of k-casein are in a homo-
logous position when compared with the human
ﬁbrinogen g-chain (Fiat & Joll"es, 1989). Casoplatelins,
which are casein-derived peptides (f106–116, f106–112
and f113–116), are inhibitors of both the aggregation of
ADP-activated platelets and the binding of human
ﬁbrinogen g-chain to a speciﬁc receptor region on the
platelet surface (Fiat & Joll"es, 1989; Joll"es et al., 1986;
Schlimme & Meisel, 1995). Furthermore, the k-casein
fragment f103–111 can prevent blood clotting through
inhibition of platelet aggregation, but is not able to
affect ﬁbrinogen binding to ADP-treated platelets (Fiat
et al., 1993).
More recently, it was reported that k-caseinoglyco-
peptides from several animal species are a source of
antithrombotic peptides. The sequence of amino acids in
f106–171 of sheep’s k-casein, known as k-caseinoglyco-
peptide, was shown to decrease thrombin- and collagen-
induced platelet aggregation in a dose-dependent
manner (Qian, Joll"es, Migliore-Samour, Schoentgen, &
Fiat, 1995). In the plasma of 5-day-old new borns, after
breast feeding or ingestion of cow’s milk-based for-
mulae, antithrombotic peptides were detected, which
had been derived from human and bovine k-caseino-
glycopeptides, respectively (Chabance et al., 1995).
Blood pressure regulation (and hypertension, when it
cannot be ensured) is partially dependent on the renin–
angiotensin system; renin acts on angiotensinogen, thus
releasing angiotensin I that is further converted into the
active peptide hormone angiotensin II, a vasoconstric-
tor, by the angiotensin-converting enzyme (ACE).
Angiotensin II inactivates bradykinin (a vasodilator);
moreover, it increases the production of aldosterone,
which decreases the renal output while increasing water
retention (Fiat et al., 1993; Maruyama et al., 1987a;
Maruyama, Mitachi, Tanaka, Tomizuka, & Suzuki,
1987b; Tirelli, de Noni, & Resmini, 1997).
Maruyama and Suzuki (1982) reported that tryptic
hydrolysates of casein inhibited the in vitro activity of
ACE; those peptides derived from casein, known as
casokinins, correspond to f23–24, f23–27 and f194–199
of bovine as1-casein B, as well as to f177–183 and f193–
202 of bovine b-casein (Maruyama & Suzuki, 1982;
Maruyama et al., 1987a,b; Meisel & Schlimme, 1994).
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Fig. 1. Functions of bioactive peptides from caseins.
Table 1
Antithrombotic peptide sequences in the primary structure of caseins
Casein Type Peptide sequence Amino acid segment References
k–casein (bovine) 103–111 LSFMAIPPK Fiat et al. (1993)
106–116 MAIPPKKNQDDK Fiat and Joll"es (1989); Joll"es et al. (1986); Schlimme and Meisel (1995)
106–112 MAIPPKK Fiat and Joll"es (1989); Joll"es et al. (1986); Schlimme and Meisel (1995)
113–116 NQDK Fiat and Joll"es (1989); Joll"es et al. (1986); Schlimme and Meisel (1995)Pihlanto-Lepp.al.a, Rokka, and Korhonen (1998) studied
the ACE-inhibitory activity of peptides from milk whey
and from casein proteins fermented with lactic acid
bacteria, and hydrolysed afterward by digestive en-
zymes; the fermentation of milk proteins by starters
did not produce ACE-inhibitory peptides, but subse-
quent hydrolysis led to ACE-inhibitory activity. Thepeptides identiﬁed were as1-casein f142–147, f157–164
and f194–199, and b-casein f108–113, f177–183 and
f193–198, as well as two others from whey proteins. The
latter two were shown to be less active than the casein-
derived peptides; among these, the highest ACE-
inhibitory activity was accounted for by the peptides
derived from as1-casein. Other anti-hypertensive
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Table 2
Antihypertensive peptide sequences in the primary structure of caseins
Casein type Peptide sequence Amino-acid segment References
as1 (bovine) 23–24 FF Maruyama and Susuki (1982); Maruyama et al. (1987a); Meisel
and Schlimme (1994)
23–27 FFVAP Maruyama and Susuki (1982); Maruyama et al. (1987a); Meisel
and Schlimme (1994)
102–109 KKYKVPQ G !omez-Ruiz et al. (2002)
142–147 LAYFYP Pihlanto-Lepp.al.a et al. (1998)
157–164 DAYPSGAW Pihlanto-Lepp.al.a et al. (1998)
194–199 TTMPLW Maruyama and Susuki (1982); Maruyama et al. (1987a); Meisel
and Schlimme (1994); Pihlanto-Lepp.al.a et al. (1998)
as2 (bovine) 174–179 FALPQY Tauzin, Miclo, and Gaillard (2002)
174–181 FALPQYLK Tauzin, Miclo, and Gaillard (2002)
189–197 AMKPWIQPK Maeno, Yamamoto, and Takano (1996)
189–193 AMKPW Maeno, Yamamoto, and Takano (1996)
190–197 MKPWIQPK Maeno, Yamamoto, and Takano (1996)
198–202 TKVIP Maeno, Yamamoto, and Takano (1996)
b (bovine) 74–76 IPP Nakamura et al. (1995)
84–86 VPP Nakamura et al. (1995)
108–113 EMPFPK Pihlanto-Lepp.al.a et al. (1998)
177–183 AVPYPQR Maruyama and Susuki (1982); Maruyama et al. (1987a); Meisel
and Schlimme (1994)
193–198 YQEPVL Pihlanto-Lepp.al.a et al. (1998)
193–202 YQEPVLGPVRGPFPI Maruyama and Susuki (1982); Maruyama et al. (1987a); Meisel
and Schlimme (1994)
199–204 GPVRGPFPIIV Nakamura et al. (1995)
k (bovine) 108–110 IPP Nakamura et al. (1995)
g–casein (bovine) 108–113 EMPFPK Perpetuo, Juliano, and Lebrun (2003)
114–121 YPVEPFTE Perpetuo, Juliano, and Lebrun (2003)peptides could be pinpointed in the primary sequence of
human b- and k-caseins (Kohmura et al., 1989;
Kohmura, Nio, & Ariyoshi, 1990; Shah, 2000).
Few studies exist concerning as2-casein—which ac-
counts for ca. 10% (w w1) of the bovine casein system,
owing to its poor solubility and difﬁcult puriﬁcation.
The few peptides already identiﬁed to derive from
bovine as2-casein exhibit weak ACE-inhibition; those
peptides correspond to f189–193, f189–197, f190–197
and f198–202 (Maeno, Yamamoto, & Takano, 1996).
Studies by Tauzin, Miclo, and Gaillard (2002) on a
tryptic digest of bovine as2-casein permitted detection of
several casokinins. Some exhibited IC50 values close to
those that characterise the most potent peptides found
in milk protein hydrolysates—two peptides, f174–181
and f174–179, had IC50 values very low compared with
that of captopril, and were inhibitors of ACE. Whether
such peptides and the whole tryptic hydrolysate arise
in vivo needs further experimental conﬁrmation (Tauzin
et al., 2002). Two new peptides generated by tryptic
hydrolysis of casein have just been found to display
bradykinin-potentiating activity on isolated guinea pig
ileum. The peptides Glu-Met-Pro-Phe-Pro-Lys and Tyr-Pro-Val-Glu-Pro-Phe-Thr-Glu originate from the g-
casein sequences, f108–113 and f114–121; the latter
showed an in vitro inhibition effect upon ACE
(Perpetuo, Juliano, & Lebrun, 2003).
Karaki et al. (1990) detected a decrease in blood
pressure in spontaneously hypertensive rats following
oral administration of tryptic hydrolysates of milk
casein. Two potent ACE-inhibitory peptides from
b-casein, f84–86 which corresponds to Val-Pro-Pro,
and f74–76 which corresponds to Ile-Pro-Pro, and one
from k-casein, f108–110 which corresponds to Ile-Pro-
Pro, were puriﬁed from ‘‘Calpis’’, a Japanese soft drink
made from bovine skim milk fermented by Lactobacillus
helveticus and Saccharomyces cerevisiae (Nakamura
et al., 1995). Those two tripeptides have been also
found in casein hydrolysates produced by extracellular
proteinase of L. helveticus CP790, and in milk inocu-
lated with L. helveticus (Yamamoto, Akino, & Takano,
1994a,b). In a placebo-controlled study, the blood
pressure of hypertensive patients decreased signiﬁcantly
after 4–8weeks of daily ingestion of 95mL of sour milk
containing such two tripeptides (Hata, Yamamoto,
Ohni, Nakajima, & Nakamura, 1996).
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product fermented by L. helveticus CPN4 containing
the sequence Tyr-Pro was identiﬁed by Yamamoto,
Maeno, and Takano (1999); it is found within as1-,
b- and k-casein primary structures. The synthetic
peptide yielded signiﬁcant antihypertensive activity
from 2 to 8 h after oral administration of 1mg of
peptide per kg of body weight of spontaneously
hypertensive rats, and this effect was further proven to
be highly dependent on the peptide dosage; however,
the peptide possessed a low inhibitory activity against
angiotensin I-converting enzyme (Yamamoto et al.,
1999).
The antihypertensive activity of casein-enriched milk,
unfermented or fermented by L. helveticus, was eval-
uated by Leclerc, Gauthier, Bachelard, Sature, and Roy
(2002); in the former situation, a signiﬁcant reduction of
blood pressure occurred, whereas the antihypertensive
activity measured in the latter case could be explained
by the release of ACE-inhibitory peptides from caseins
during the digestion process.
Several bioactive peptides with ACE-inhibitory activ-
ity have also been found in cheese; their appearance is
inﬂuenced by proteolysis, but only to a certain degree.
An as1-casein-derived antihypertensive peptide isolated
from Parmesan cheese by 6 months of ripening could
not be found after 15 months (Addeo et al., 1992).
Accordingly, the antihypertensive activity found in
long-ripened Gouda cheese was half that found in
its medium-aged counterpart (Meisel, Goepfert, &
G .unther, 1997). Partially consistent with these ﬁndings
are those reported by G !omez-Ruiz, Ramos, and Recio
(2002), when studying the ACE-inhibitory peptides in
Manchego cheese manufactured with various starter
cultures; the anti-hypertensive activity decreased within
the ﬁrst 4 months, was maximum by 8 months of
ripening and decreased again towards 12 months. The
protein fragments responsible for such activity were
mainly low-molecular-weight peptides; a speciﬁc interest
arose regarding f199–204 from b-casein and f102–109
from as1-casein. Peptides isolated from Italian cheeses,
namely Italico and Gorgonzola, were also found
inhibitory of ACE activity (Smacchi & Gobbeti, 1998).
Following isolation from Gouda cheese, Saito, Naka-
mura, Kitazawa, Kawai, and Itoh (2000) analysed the
structure of the antihypertensive features of a few
peptides, and concluded that the strongest depressive
effect on the systolic blood pressure and the highest
ACE-inhibitory capacity is associated to peptides found
in 8-months-old cheese.
Several new oligopeptides were identiﬁed after extrac-
tion, semi-quantiﬁcation and fast on-line identiﬁcation
by HPLC-MS of samples of Grana Padano cheese.
Some of them contained bioactive sequences showing
potential biological activity (Sforza, Ferroni, Galaverna,
Dossena, & Marchelli, 2003).A new type of ripened, low-fat cheese called ‘‘Festivo’’
was manufactured with classical starter cultures, in
combination with L. acidophilus and biﬁdobacteria.
Such a novel cheese possesses multifactorial health
effects; it contains several beneﬁcial components,
e.g. bioactive peptides with potential antihypertensive
effects, probiotics, conjugated linoleic acid and bioavail-
able calcium (Ryh.anen, Pihlanto-Lepp.al.a, & Pahkala,
2001). Conversely, cheeses characterized by low levels of
proteolysis, viz. Quark, exhibit low ACE-inhibitory
capacity (Meisel et al., 1997).
As already mentioned, some peptides may contain
several different bioactivities; studies encompassing
puriﬁcation and identiﬁcation of potentially bioactive
peptides from enzyme-modiﬁed cheese (EMC) (Hailese-
lassie, Lee, & Gibbs, 1999) showed that b-casomorphin,
as well as other hydrophobic peptides released by
Neutrases, might serve as precursors for antihyperten-
sive peptides; this realization suggests that EMC may be
an alternative vehicle for production of that class of
compounds.
The ACE-inhibitory peptides derived from dairy
products are not as potent as the drugs commonly used
for hypertension treatment; however, those products
that hold a moderate bioactivity behave intrinsically
(and naturally) as functional foods, so they can easily be
included in the daily diet (Meisel et al., 1997).It is a common belief that falling asleep is easier after
drinking a glass of milk in the evening, and that babies
are soothed after breast or bottle feeding. Recent studies
have provided evidence that peptides exist in dairy
products which play an active role in the nervous
system; known as opioid peptides, they can have
agonistic or antagonistic activities (Table 3).
Located in the nervous endocrine (and also in the
immune) system, as well as in the intestinal tract of
mammals, opioid receptors (of the m-, d- and k-type)
interact with endogenous or exogenous ligands. The
former, called ‘‘typical’’ opioid peptides, e.g. enkepha-
lin, endorphin and dynorphin, are derived from the
precursor molecules proopiomelanocortin, proenke-
phalin and prodynorphin, respectively, and all share
the typical N-terminal sequence Tyr-Gly-Gly-Phe. The
latter, or ‘‘atypical’’ opioid peptides, have agonistic
(exorphins, or formons—‘‘food hormones’’) or antag-
onistic (casoxins) activities, and are characterized by
distinct N-terminal sequences. The common structural
feature of endogenous and exogenous opioid peptides
(except a-casein opioids) is the presence of a Tyr residue
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Table 3
Opioid peptide sequences in the primary structure of caseins
Casein type Peptide sequence Amino-acid segment References
Agonistic peptides
as1 (bovine) 90–95 RYLGYL Loukas et al. (1983)
90–96 RYLGYLE Loukas et al. (1983)
91–95 YLGYL Loukas et al. (1983)
b (human) 41–44 YPSFQ Fiat et al. (1993)
g (casein) 114–121 YPVEPFTE Perpetuo et al. (2003)
Antagonistic peptides
k (bovine) 35–41 YPSYGLN Xu (1998)
58–61 YPYY Xu (1998)
25–34 YIPIQYVLSR Xu (1998)
158–164 EINTVQV Xu (1998)at the N-terminus, coupled with the presence of another
aromatic residue, e.g. Phe or Tyr, in the third or fourth
position. This is an important structural feature, that
ensures ﬁtting into the binding site of opioid receptors;
furthermore, the negative potential, localized in the
vicinity of the phenolic hydroxyl group of tyrosine,
seems to be essential for opioid activity—absence of
bioactivity was indeed noticed when no tyrosine residue
exists (Meisel, 1998).
Several authors have compiled information regarding
opioid receptor ligands derived from food proteins,
especially milk caseins (Teschemacher, 2003; Tesche-
macher, Koch, & Brantl, 1997), and different opinions
arised concerning the nature of the ligand–receptor
interaction; hence, suitability of models for the determi-
nation of bioactive conformation of peptide ligands
active towards m-opioid receptors have been discussed
(Gentilucci & Tolomelli, 2004).
The major and the ﬁrst opioid peptides discovered are
the so-called b-casomorphins (Brantl, Teschemacher,
Henschen, & Lottspeich, 1979), which are fragments of
b-casein between the 60th and the 70th residues, mainly
f60–63, f60–64, f60–65, f60–66 and f60–70 (Smacchi &
Gobbettti, 2000); these peptides were characterized as
m-type ligands (Teschemacher & Brantl, 1994). Longo-
bardo et al. (2000) reported that replacement of Phe in
position 3 of two analogues of bovine b-casomorphin-7
and -5 by a b-homo-Phe enhanced the m-type opioid
receptor afﬁnity as compared to the natural peptides, by
5- and 2-fold, respectively; the most potent is the
pentapeptide b-casein f60–64 (Fiat et al., 1993). A
similar amino-acid sequence appears in b-casein from
sheep milk (Richardson & Mercier, 1979) and water
buffalo milk (Petrilli, Addeo, Chianese, 1983). The
sequence f41–44 from human milk b-casein was also
claimed to be an opioid peptide, called b-casomorphin,
holding agonistic activity (Fiat et al., 1993).Three as-casein-derived exorphins, which typically
correspond to bovine as1-casein f90–95, f90–96 and
f91–96, were found to be d-selective receptor ligands
(Loukas, Varoucha, Zioudrou, Streaty, & Klee, 1983).
More rencently, Perpetuo et al. (2003) reported a new
peptide from g-casein, Tyr-Pro-Val-Glu-Pro-Phe-Thr-
Glu, possessing in vitro opiate-like activity, which was
generated by tryptic hydrolysis of casein.
Opioid peptides from milk can be obtained in vitro by
proteolysis of bovine as-, b- and k-caseins (Pihlanto-
Lepp.al.a, Antila, Mantsala, & Hellman, 1994). Sequen-
tial digestion brought about by pepsin and trypsin
increases the overall degree of proteolysis, which
generates hydrolysates with stronger antimicrobial or
antihypertensive activities than a single enzyme treat-
ment (Pihlanto-Lepp.al.a et al., 1998; Pihlanto-Lepp.al.a,
Marnila, Hubert, Rokka, & Korhonen, 1999).
Studies in vivo have also been performed with opioid
agonist peptides. Ermisch, Ruhle, Neubert, Hartrodt,
and Landgraf (1983) have shown that, following
intracarotid injection of [3H]b-casomorphin-5 in rats,
this compound accumulated to a relatively high degree
in the areas free of blood–brain barrier. Higher amounts
of b-casomorphin-7 were also encountered in blood
from newborn calves, under the form of a precursor
(Fiat et al., 1993).
Meisel and Frister (1989) detected b-casomorphins in
the intestinal chyme of minipigs, as well as in the small
intestine of humans after ingestion of cow’s milk
(Svedberg, de Haas, Leimenstoll, Paul, & Teschemacher,
1985). Since their absorption in the gut has not been
reported to date, it is generally accepted that physiolo-
gical inﬂuences are restricted to the gastrointestinal
tract, where they may modulate gastrointestinal func-
tion, intestinal transit, amino-acid uptake and water
balance. As soon as peptides enter the blood stream,
they are believed to be quickly hydrolysed (Meisel,
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pass through the intestinal mucosa in neonates via
passive transport, so babies may become calm and
sleepy (Sturner & Chang, 1988). In pregnant or lactating
women, the mammary tissue is also permeable to
b-casomorphin (Clare & Swaisgood, 2000). Chabance
et al. (1998) showed that many peptides from as1-, b-, k-
casein and k-caseinomacropeptide exist in the stomach
of adults following consumption of milk or yoghurt, and
some fragments of casein were also found in the
duodenum. Moreover, the k-caseinoglycopeptide and
the N-terminal peptide of as1-casein were shown to be
absorbed, and were accordingly detected in the plasma.
Exorphins exhibit pharmacological properties similar
to opium (morphine), and exert naloxone-inhibitable
activities (Meisel & Schlimme, 1990); they also induce
apnea and irregular breathing, modulate sleep patterns,
stimulate pancreatic insulin and gastrointestinal soma-
tostatin release, modulate animal behaviour, stimulate
intestinal absorption of electrolytes and water, modulate
intestinal motility, and stimulate food intake by
modifying the endocrine activity of the pancreas, hence
causing an increase of insulin output (Xu, 1998).
Recently, Sun et al. (2003) reviewed novel ﬁndings
concerning the possible association between b-casomor-
phin and apnea in sudden infant death syndrome.
The b-casomorphin immunoreactive material was ﬁrst
identiﬁed by Hamel, Kielwein, and Teschmacher (1985)
in cow’s milk, that had been incubated with various
bacterial species including lactic acid bacteria. Matar
and Goulet (1996) produced fermented milk enriched
with the (opioid) b-casomorphin 1–4 (f60–63) using a
mutant strain of L. helveticus that lacks X-prolyl-
dipeptidyl-aminopeptidase activity. In cheese, b-caso-
morphins are further hydrolysed in a gradual manner
via the proteolytic enzymes of Lactococcus lactis subsp.
cremoris during ripening; this process is strongly
dependent on pH and salt concentration prevailing in
that dairy product (Muehlenkamp & Warthesen, 1996).
Opioid antagonists are those peptides that suppress
the agonist activity of enkephalin; known as casoxins,Table 4
Immunomodulating peptide sequences in the primary structure of caseins
Casein type Peptide sequence Amino-acid segment
as1 (bovine) 1–23 RPKHPIKHQGLPQEVLNENLLRF
194–199 TTMPLW
as2 (bovine) 1–32 KNTMEHVSSSEESIISQETYKQEKNM
b (bovine) 1–28 RELEELNVPGEIVESLSSSEESITRIN
63–68 PGPIPN
191–193 LLY
193–209 LLYQEPVLGPVRGPFPIIV
b (human) 54–59 VEPIPYthey have been found in both bovine and human k-
casein, as well as in as1-casein (Chiba, Tani, &
Yoshikawa, 1989; Yoshikawa et al., 1994). Two bovine
casoxins are opioid receptor ligands of the m-type, with
relatively low antagonistic potency as compared with
naloxone (Meisel, 1998). Casoxins A and B correspond
to amino-acid sequences within bovine k-casein; casoxin
A corresponds to f35–41 of k-casein (i.e. Tyr-Pro-Ser-
Tyr-Gly-Leu-Asn), whereas casoxin B is accounted for
by f58–61 of k-casein (i.e. Tyr-Pro-Tyr-Tyr). Casoxin C
is an opioid antagonist obtained from tryptic digests of
bovine k-casein; its sequence corresponds to f25–34 (i.e.
Tyr-Ile-Pro-Ile-Gln-Tyr-Val-Leu-Ser-Arg), and pos-
sesses the highest biological potency (Xu, 1998).
Casoxin D was generated from as1-casein (Clare &
Swaisgood, 2000). Some casoxins were modiﬁed by
methoxylation during the process of isolation and
puriﬁcation; they were proven to be more active
than the corresponding C-terminal, non-methoxylated
k-casein fragment (Schlimme & Meisel, 1995).The systems involved in the human body’s defense
against invaders are rather complex; diet is known to
play an important role therein. Research concerning the
role of functional peptides in this ﬁeld is quite recent,
but it already seems very promising. The two main
activities are the immunomodulatory one (i.e. stimula-
tion of the immune system) (Table 4) and the
antimicrobial one (i.e. inhibition of pathogenic bacteria)
(Table 5).
Breast feeding facilitates physical transmission of
passive immunity via a number of multifunctional
factors, which have a direct effect on the neonate’s
resistance to bacterial and viral infections; caseins are
included among these factors. In fact, during enzymaticReferences
Minkiewicz et al. (2000)
Migliore-Samour and Joll"es (1988); Parker et al. (1984)
AINPSK Hata et al. (1999)
K Hata et al. (1999)
Migliore-Samour and Joll"es (1988); Parker et al. (1984)
Migliore-Samour and Joll"es (1988); Parker et al. (1984)
Minkiewicz et al. (2000)
Parker et al. (1984)
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Table 5
Antimicrobial peptide sequences in the primary structure of caseins
Casein type Peptide sequence Amino-acid segment References
as1 (bovine) 1–23 RPKHPIKHQGLPQEVLNENLLRF Lahov and Regelson (1996)
as2 (bovine) 164–179 LKKISQRYQKFALPQY Recio and Visser (1999)
165–203 KKISQRYQKFALPQYLKTVYQHQKAMKPWIQPKTKVIPY Zucht et al. (1995)
183–207 VYQHQKAMKPWIQPKTKVIPYVRYL Recio and Visser (1999)
b (bovine) 193–209 YQEPVLGPVRGPFPIIV Sandre et al. (2001)digestion of human and bovine milk caseins, peptides
with immunomodulating capacities are released. Joll"es
et al. (1981) were the ﬁrst to report that extracts of
trypsin-hydrolysed human milk possess immunostimu-
lating activity; in particular, the hexapeptide Val-Glu-
Pro-Ile-Pro-Tyr, corresponding to f54–59 of human
milk b-casein, was isolated from its tryptic hydrolysate
(Parker et al., 1984) and proven to account for such an
activity—it is noteworthy that this peptide represents
the C-terminal part of b-casomorphin-11. Several
other peptides were later isolated, namely f63–68 and
f191–193 from bovine b-casein, and f194–199 from
bovine as1-casein (Migliore-Samour & Joll"es, 1988;
Parker et al., 1984). All the aforementioned peptides
stimulate phagocytic activity of murine and human
macrophages in vitro, and exert a protective effect
against Klebsiella pneumoniae infection in mice in vivo
(Migliore-Samour, Floch, & Joll"es, 1989). More
recently, the pH 4.6-soluble products from the hydro-
lysis of whole bovine casein by chymosin encompassed
peptides possessing immunomodulatory activity, i.e.
as1-casein f1–23 and b-casein f193–209 (Minkiewicz,
Slangen, Dziuba, Visser, & Mioduszewska, 2000). A
tripeptide from k-casein increased signiﬁcantly the
proliferation of human peripheral blood lymphocytes
in vivo (Kayser & Meisel, 1996), whereas the C-terminal
sequence of bovine b-casein (f193–209), containing
b-casokinin-10, induced similar results in rats (Coste
et al., 1992).
Bioactive peptides present in yoghurt actually de-
creased cell proliferation with IEC-6 or Caco-2 cells,
which may explain, at least partially, why consumption
of yoghurt has been associated with a reduced incidence
of colon cancer (Ganjam, Thornton, Marshall, &
MacDonald, 1997). Ru zhen, a product containing
bioactive protein and colostral polypeptides, was proved
to possess immunomodulatory activity and the potential
to improve resistance to disease (Zhang, Hou, & Su,
1998). Meisel and G .unther (1998) reported that milk
proteins are precursors of peptides that modulate the
activity of human cells, after having investigated the
modulating activity of peptides corresponding to bioac-
tive sequences of casein and a lyophilised extract of
Gouda cheese.A commercially available caseinophosphopeptide
preparation CPP-III, consisting mainly of f1–32 of
bovine as2-casein and f1–28 of b-casein, enhances the
proliferative response induced by lipopolysaccharide,
phytohaemagglutinin and concavalin A stimulation, and
immunoglobulin production in mouse spleen cell cul-
tures; this immunostimulating activity was attributed to
the o-phospho-l-serine residue, hence suggesting that
such a bioactivity is relatively stable to proteinase action
in the intestinal tract (Hata, Ueda, & Otani, 1999).
Studies focusing on the effects of CPP-III on serum and
intestinal immunoglobulin G and immunoglobulin A in
mice proved that oral use of caseinophosphopeptide is
beneﬁcial toward enhancement of the mucosal immunity
(Otani, Kihara, & Minkyu, 2000).
Matar, Valdez, Medina, Rachid, and Perdigon (2001)
studied the effects of milks fermented by L. helveticus
and its non-proteolytic variant on mucosal and tumoral
immunity, via oral administration of milk to mice (3mL
per mouse per day) for 3, 5 and 7 days. Lactic acid
bacteria apparently show important implications upon
modulation of the host’s immune response, mainly its
cellular one, because they are responsible for release of
bioactive peptides. Three fractions from the aforemen-
tioned fermented milk were then isolated and fed to mice
for various periods (2, 5 and 7 days), and the effect
thereof on their tumoral immune system and on
ﬁbrosarcoma growth was duly analysed (LeBlanc,
Matar, Valdez, LeBlanc, & Perdig !on, 2002). The
mechanism by which lactic acid bacteria enhance the
immune system is not yet clear, but it is accepted that
bioactive compounds released in fermented milks
contribute to the immunoenhancing and antitumour
properties of these dairy products.
Supplementation of infant formulae with appropriate
milk proteins, viz. caseinomacropeptide, may help to
promote growth of a host-friendly colonic microﬂora,
mainly biﬁdobacteria or lactobacilli, and may help to
overcome some enteric infections (Bruck, Graverholt, &
Gibson, 2003; Bruck et al., 2003).
Nowadays, the mechanism, structure and activity by
which milk protein-derived peptides exert their immu-
nomodulatory effect is still questionable. However, the
Arg residue at the N- or C-terminal region of a peptide
ARTICLE IN PRESShas been suggested to be the leading motif recognizable
by speciﬁc surface membrane receptors; in this context,
it is worth noting that the immunomodulatory ACE-
inhibitor peptide b-casokinin-10 (among other ACE-
inhibitory peptides) has Arg in its C-terminus. Opioid
peptides are also thought to affect the immunoreactivity
of lymphocytes via opiate m-receptors, which, for
endorphins, are present on T-lymphocytes and human
phagocytic leucocytes (Meisel, 1998).
In vitro inhibition of growth of pathogenic strains
occurs in the presence of as2-casein or lactoferricin
fragments (Tomita, Takase, Bellami, & Shimamura,
1994; Zucht, Raida, Adermann, Magert, & Forssman,
1995). Caseicidin, obtained by chymosin-mediated
digestion of casein at neutral pH, was among the ﬁrst
defence peptides actually puriﬁed—it exhibited activity
against Staphylococcus spp., Sarcina spp., Bacillus
subtilis, Diplococcus pneumoniae and Streptococcus
pyogenes (Lahov & Regelson, 1996). A cationic frag-
ment from as2-casein, f165–203, known as casocidin-I,
can inhibit growth of Escherichia coli and S. carnosus
(Zucht et al., 1995). Two other peptides were meanwhile
isolated from a peptic hydrolysate of as2-casein, namely
f183–207 and f164–179; the former exhibited higher
antimicrobial activity than the latter, although both
possessed comparable hemolytic effects (Recio & Visser,
1999). Lactoferricin, or f17–41 from lactoferrin pro-
duced by enzymatic cleavage brought about by pepsin,
was shown to possess more potent bactericidal proper-
ties than the undigested, iron-binding glycoprotein
present in most biological ﬂuids of mammals, including
milk (Meisel, 1998).
The other fragment of as1-casein, viz. f1–23, known as
isracidin, has demonstrated antibiotic-type activity
in vivo versus S. aureus and Candida albicans; it canTable 6
Caseinophosphopeptide sequences in the primary structure of caseins
Casein type Peptide sequence Amino-acid segm
as1 (bovine) 43–58 DIGSESTEDQA
45–55 GSESTEDQAM
59–79 QMEAESISSSE
66–74 SSSEEIVPN
106–119 VPQLEIVPNSA
as2 (bovine) 2–21 NTMEHVSSSEE
46–70 NANEEEYSIGS
55–75 GSSSEESAEVA
126–136 EQLSTSEENSK
138–149 TVDMESTEVF
b (bovine) 1–25 RELEELNVPG
1–28 RELEELNVPG
2–28 ELEELNVPGEIprotect sheep and cows against mastitis (Lahov &
Regelson, 1996). Fragments of human b-casein have
also a protective effect against Klebsiella pneumoniae in
mice (Migliore-Samour et al., 1989). The immunomo-
dulatory peptide derived from bovine b-casein, viz.
f193–209, was shown to enhance the antimicrobial
activity of mouse macrophages, which had been
obtained either from germ-free or from human ﬂora-
associated mice, without proinﬂammatory effects
(Sandre et al., 2001).
All these results pertaining to animals have been
obtained in vivo by injecting peptides therein; at present,
no studies are yet available that provide evidence for
their putative effect when ingested.Some peptides are able to sequester calcium and other
minerals, hence acting as biocarriers—they are called
phosphopeptides (Table 6); glycomacropeptide (GMP)
may also exhibit a number of nutritional features; both
are discussed below.
The term phosphopeptide was pioneered by Mella-
nder (1950), and it means a casein-derived phosphory-
lated peptide which enhances vitamin D-independent
bone calciﬁcation in rachitic infants. Chabance et al.
(1998) have proven the occurrence of caseinopho-
sphopeptides (CPPs) in the stomach and duodenum
following milk ingestion. CPPs have also been found
after in vitro and/or in vivo digestion of as1-, as2- or
b-casein (Kitts, 1994); f43–58, f45–55, f59–79, f66–74
and f106–119 from as1-casein, f2–21, f46–70, f55–75,
f126–136 and f138–149 from as2-casein, and f1–25, f1–28
and f2–28 from b-casein have been reported in thisent References
MEDIK Smacchi and Gobbetti (2000)
E Smacchi and Gobbetti (2000)
EIVPNSVEQK Smacchi and Gobbetti (2000)
Smacchi and Gobbetti (2000)
EER
SIISQETYK Smacchi and Gobbetti (2000)
SSEESAEVATEEVK Smacchi and Gobbetti (2000)
TEEVKITVDD Smacchi and Gobbetti (2000)
Smacchi and Gobbetti (2000)
TK Smacchi and Gobbetti (2000)
EIVESLSSSEESITR Smacchi and Gobbetti (2000)
EIVESLSSSEESITRINK Smacchi and Gobbetti (2000)
VESLSSSEESITRINK Smacchi and Gobbetti (2000)
ARTICLE IN PRESSparticular (Smacchi & Gobbetti, 2000). Certain CPPs
were for the ﬁrst time detected in ileostomy ﬂuid by
Meisel et al. (2003), which conﬁrms the ability of such
peptides to survive gastrointestinal passage to the
human distal ileum. In addition to their presence in
whole milk, CPPs have also been claimed to be released
by proteolytic enzymes of lactic acid bacteria during
ripening of such cooked curd cheeses as Grana Padano
(Pellegrino et al., 1997) and Comte´ (Roudot-Algaron, le
Bars, Kerhoas, Einhorn, & Gripon, 1994).
Recently, Meisel and FitzGerald (2003) have reviewed
the structural features and physiological potential of
milk-protein-derived caseinophosphopeptides, which
were also shown to exert cytomodulatory effects.
The phosphate residues, corresponding to ca. 30% of
the phosphorus content in milk, are present as
monoesters of Ser and occur mainly in clusters;
most CPPs share a common feature, i.e. they are
constituted by a sequence of three phosphoseryl
residues, followed by two glutamic acid residues, viz.
SerP-SerP-SerP-Glu-Glu (Meisel, Frister, & Schlimme,
1989; Meisel, 1997).
The high concentration of negative charges of
phosphate peptides makes them resistant to further
proteolysis (Clare & Swaisgood, 2000; Reynolds, Riley,
& Adamson, 1994; Meisel & Schlimme, 1990; Hirayama,
Toyota, Yamaguchi, Hidaka, & Naito, 1992; Kasai,
Honda, & Kiriyama, 1992; Kasai, Iwasaki, Tanaka, &
Kiriyama, 1995; FitzGerald, 1998).
Furthermore, the negatively charged side chains, in
particular the phosphate groups, of those amino acids
represent the binding sites for minerals (Meisel, 1998);
CPPs have been shown to bind to such macroelements
as Ca, Mg and Fe, as well as to such oligoelements as
Zn, Ba, Cr, Ni, Co and Se. However, the Ca-binding
activity of the phosphopeptide fractions of casein can be
different—which may be attributed to the inﬂuence of
further amino acids around the phosphorylated binding
sites (Meisel, 1998).
Iron deﬁciency, a major worldwide nutritional pro-
blem, can be reduced by CPPs; in fact, binding of Fe to
phosphopeptides prevents formation of high-molecular-
weight ferric hydroxides, which are poorly absorbed. In
vitro studies with rats (Ait-Oukhatar et al., 1999) have
demonstrated that Fe bound to the phosphoserine
residues of low-molecular-weight CPPs, namely b-casein
f1–25, improved their ability to treat anaemia and
restore Fe storage tissues, when compared with Fe
bound to whole casein and inorganic salts. Further
studies in vivo (Ait-Oukhatar et al., 2002), using
radiolabelled iron, assessed Fe absorption and uptake
by tissues involved in Fe metabolism and storage; the
metabolism of b-casein f1–2559[Fe], added to cows’ milk
was studied in young women—absorption thereof was
not signiﬁcantly above that of ferrous sulfate, but a
signiﬁcantly higher, transient tissue uptake was noticedthat vanished by 14 days (hence suggesting that iron was
used for metabolic purposes).
Zinc absorption can also be enhanced if that metal is
bound to CCPs, namely b-casein f1–25; moreover, its
inhibition by such other nutrients as Fe is prevented
(Peres et al., 1998). An increase in Ca and Zn absorption
was noticed after CPP incorporation into rice-based
infant food, during a human feeding trial (Meisel &
Bockelmann, 1999; Hansen, Sandst .om, Jensen, &
S .orensen, 1997).
Milk and dairy products provide plenty of Ca2+,
which can form soluble complexes with those phospho-
peptides, thus avoiding Ca phosphate precipitation
(Sato, Naguchi, & Naito, 1986; Berrocal et al., 1989),
and enhancing intestinal absorption of Ca and retention
thereof in the body (Mykk.anen & Wasserman, 1980;
Sato et al., 1986). According to Meisel (1997), binding of
Ca involves Ser-bound phosphate groups, as well as the
free carboxyl groups of Glu; the hydrophobic tail
protects this complex from further interactions, and
hence prevents formation of insoluble calcium phos-
phate. Ferraretto, Signorile, Gravaghi, and Fiorilli
(2001) found out that casein phophopeptides inﬂuence
calcium uptake by cultured human intestinal HT-29
tumor cells. Chemically synthesized casein phosphopep-
tides b-casein (1–25)4P and as1-CN(59–79)5P, carrying
the characteristic ‘‘acid motif’’ Ser(P)-Ser(P)-Ser(P)-
Glu-Glu, were found to cause an increase of Ca2+
concentration due to inﬂux of extracellular Ca2+, the
effect being more pronounced with the b-casein-derived
petide than with as1-casein-derived one. Moreover, the
CPP-promoting effect on calcium concentration was
proven to depend on the structural conformation
conferred by both the phosphorylated ‘‘acidic motif’’
and the preceding N-terminal portion (Ferraretto,
Gravaghi, Fiorilli, & Tettamanti, 2003).
It has been shown that Ca-binding phosphopeptides
have anticariogenic effects via inhibition of caries lesion
through recalciﬁcation of the dental enamel—hence,
their application in the treatment of dental diseases has
been proposed (Clare & Swaisgood, 2000; Reynolds,
1987; Tirelli et al., 1997), namely as additives to
toothpaste (Reynolds, 1994). The consumption of cheese
has an anticariogenic effect as well; a signiﬁcant
correlation was found between the high content of
casein in cheese and the caries-protective effect thereof
(Pause & Lembke, 1993). Moreover, anticariogenic
activity has also been reported for phosphopeptides
from eggs (viz. phosvitin and phosphophorin) (Rey-
nolds, 1994; Tirelli et al., 1997).
Heating processes affect the bioavailability of CPPs;
sterilization can induce dephosphorylation of phospho-
seryl residues that occur in clusters, and formation of
dehydroalanine from residues occupying isolated posi-
tions in the peptide chain (Meisel, Andersson, Buhl,
Erbersdobler, & Schlimme, 1991).
ARTICLE IN PRESSThe glycomacropeptide (GMP) is formed during the
enzymatic cheesemaking process. Rennet or chymosin
hydrolyses the peptide bond between residues 105 and
106 of k-casein, and the resulting molecule, GMP, is
eluted in the whey. This molecule contains residues
106–169 of k-casein; the C-terminal portion of said
molecule is more hydrophilic, as it contains the
oligosaccharides that are O-linked to threonine and
serine. The large GMP molecule cannot be absorbed as
such, so it has to be broken down into smaller peptides
before an effect on blood components arises. GMP is
unique in its amino-acid composition—it lacks aromatic
amino acids and is rich in branched chain ones.
Besides the various bioactivities displayed by GMP
(or smaller peptides derived therefrom), which were
already referred to above where appropriate, a number
of beneﬁcial effects upon the nutrition system can be
claimed. El Salam, El-Shibiny, and Buchheim (1996)
indicated that GMP might be useful for diets aimed at
controling several liver diseases, in cases where branched
chain amino acids appear to be used as a carbon source.
Stan, Ekimovskii, Aleinik, and Zhuravlev (1988) showed
that pepsin hydrolysis produced several different peptides
with distinct physiological activities. One of these is an
opioid effect, and another is a satiety effect when
administered to starving animals; the latter effect was
similar to that exhibited following cholecystokinin injection.
A well-known disease in infants fed with whey protein-
predominant formulae is hyperthreoninemia. Sweet
whey, containing not only whey proteins but also the
threonine-rich GMP, is commonly used for the manu-
facture of those formulae. Rigo et al. (2001) tested an
experimental formula based on acid whey without GMP,
against a formula based on whey with GMP upon
threonine metabolism; acid whey formulae are accord-
ingly recommended for feeding preterm infants. Later
on, Fanaro and Vigi (2002) emphasized that removal of
GMP from whey is recommended towards the develop-
ment of infant formulae closer to human milk.
Glycomacropeptide is also known to allow absorption
of calcium, iron or zinc. Kelleher, Chatterton, Nielsen,
and Lonnerdal (2003) studied GMP and a-lactalbumin
supplementation of infant formulae on the nutritional
status in infant rhesus monkeys, and found that both
increase zinc absorption—which may allow reduction of
formula zinc concentrations and promote a plasma
amino-acid pattern similar to that of breastfed infant
monkeys, respectively.There are four main physiological issues that casein-
derived bioactive peptides can address: the cardiovas-cular system, the nervous system, the immune system
and the nutrition system. Such bioactive peptides have
been proven to possess antithrombotic, antihyperten-
sive, opioid, immunomodulatory and antimicrobial
activities. Casein-derived peptides have already met
with interesting applications, both as dietary supple-
ments in functional foods and as pharmaceutical
preparations. However, whether bioactive peptides are
beneﬁcial and desirable as food constituents or as drugs
is a matter that should be carefully examined on a case-
to-case basis. Moreover, adverse effects associated with
bioactive peptides should be carefully considered,
namely if incorporated in functional food formulation
at concentrations not attainable by ingestion of original
milk products. The possibilities for designing new
dietary products and natural drugs look promising.
Future research should thus deepen existing knowledge
of the molecular mechanisms underlying distinct bioac-
tivities, and focus on the physiological functions of milk-
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